Insmed (INSM) shares rose sharply after Morgan Stanley increased its price target for the stock by 28%. The move reflects renewed optimism about the pharmaceutical company's prospects.
- Morgan Stanley raised INSM's price target by 28%
- INSM stock price jumped following the upgrade
Sign up free to read the full analysis
Create a free account to unlock full AI-curated market articles, personalized alerts, and more.